Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dimitrios A Pappas

Showing results (51-60 of 76) with videos related to

Pageof 8
Sort By:
Annals of the Rheumatic Diseases|July 29, 2020
Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry studyDimitrios A Pappas, Gregory St John, Carol J Etzel, et al.
Annals of the Rheumatic Diseases|October 13, 2020
Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registryKevin L Winthrop, Gustavo Citera, David Gold, et al.
Plos One|January 24, 2019
Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritisSiri Lillegraven, Jeffrey D Greenberg, George W Reed, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 18, 2024
Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid ArthritisJoshua F Baker, George Reed, Ted R Mikuls, et al.
American Health & Drug Benefits|June 19, 2018
Delayed Treatment Acceleration in Patients with Rheumatoid Arthritis Who Have Inadequate Response to Initial Tumor Necrosis Factor Inhibitors: Data from the Corrona RegistryDimitrios A Pappas, Robert A Gerber, Heather J Litman, et al.
Clinical Rheumatology|April 15, 2023
Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA RegistryAnthony Sebba, Clifton O Bingham, Vivian P Bykerk, et al.
RMD Open|October 26, 2024
Disease response in rheumatoid arthritis across four biologic therapies associates with improvement in paraoxonase-1 activity and oxylipinsAmir A Razmjou, Joel M Kremer, Dimitrios A Pappas, et al.
Arthritis Research & Therapy|April 28, 2016
Identifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendationsLeslie R Harrold, George W Reed, Joel M Kremer, et al.
International Immunopharmacology|December 28, 2020
Associations between an expanded autoantibody profile and treatment responses to biologic therapies in patients with rheumatoid arthritisAlison D Petro, Joseph Dougherty, Bryant R England, et al.
Cellular & Molecular Immunology|January 29, 2026
TWEAK receptor (Fn14) exacerbates TNF-α-induced inflammation in rheumatoid arthritis synovial fibroblasts and influences response to anti-TNF-α therapyFarheen S Shaikh, Meena A Shanta, Anil K Singh, et al.
Pageof 8

Showing results (51-60 of 76) with videos related to

Sort By:
Pageof 8
Annals of the Rheumatic Diseases|July 29, 2020
Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry studyDimitrios A Pappas, Gregory St John, Carol J Etzel, et al.
Annals of the Rheumatic Diseases|October 13, 2020
Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registryKevin L Winthrop, Gustavo Citera, David Gold, et al.
Plos One|January 24, 2019
Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritisSiri Lillegraven, Jeffrey D Greenberg, George W Reed, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 18, 2024
Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid ArthritisJoshua F Baker, George Reed, Ted R Mikuls, et al.
American Health & Drug Benefits|June 19, 2018
Delayed Treatment Acceleration in Patients with Rheumatoid Arthritis Who Have Inadequate Response to Initial Tumor Necrosis Factor Inhibitors: Data from the Corrona RegistryDimitrios A Pappas, Robert A Gerber, Heather J Litman, et al.
Clinical Rheumatology|April 15, 2023
Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA RegistryAnthony Sebba, Clifton O Bingham, Vivian P Bykerk, et al.
RMD Open|October 26, 2024
Disease response in rheumatoid arthritis across four biologic therapies associates with improvement in paraoxonase-1 activity and oxylipinsAmir A Razmjou, Joel M Kremer, Dimitrios A Pappas, et al.
Arthritis Research & Therapy|April 28, 2016
Identifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendationsLeslie R Harrold, George W Reed, Joel M Kremer, et al.
International Immunopharmacology|December 28, 2020
Associations between an expanded autoantibody profile and treatment responses to biologic therapies in patients with rheumatoid arthritisAlison D Petro, Joseph Dougherty, Bryant R England, et al.
Cellular & Molecular Immunology|January 29, 2026
TWEAK receptor (Fn14) exacerbates TNF-α-induced inflammation in rheumatoid arthritis synovial fibroblasts and influences response to anti-TNF-α therapyFarheen S Shaikh, Meena A Shanta, Anil K Singh, et al.
Pageof 8